William Blair analyst Tim Lugo maintained a Buy rating on Sarepta Therapeutics (NASDAQ: SRPT) today. The company’s shares opened today at $160, close to its 52-week high of $176.50.
According to TipRanks.com, Lugo is a 4-star analyst with an average return of 21.0% and a 45.8% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Atara Biotherapeutics, and Ovid Therapeutics Inc.
Currently, the analyst consensus on Sarepta Therapeutics is Strong Buy and the average price target is $122.67, representing a -23.3% downside.
In a report issued on June 15, BTIG also initiated coverage with a Buy rating on the stock with a $120 price target.
See today’s analyst top recommended stocks >>
Based on Sarepta Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $35.36 million. In comparison, last year the company had a net profit of $84.09 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare neuromuscular diseases. It focuses on the development of its potentially disease-modifying Duchenne Muscular Dystrophy drug candidates.
Read More on SRPT:
